secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024479
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences Q3 net loss $11.4M; cash $90.4M; enrollment milestones updated
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments totaled $90.4M as of Sept 30, 2022.
- Net loss for Q3 2022 was $11.4M, flat YoY; R&D expenses $8.8M vs $8.6M.
- CAHmelia-203 approaching 50% enrollment; CAHmelia-204 surpassed 25% enrollment.
- Appointed Saba Sile, M.D., as VP of Clinical Development from Horizon Therapeutics.
- Topline results expected: PCOS trial H1 2023; CAHmelia-203 H2 2023; CAHmelia-204 H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017022024479/0000950170-22-024479-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017022024479/sprb-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024479

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer